Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503

NovaBridge Biosciences

10/10/2023 13:45

Oct 10 (Reuters) - ABL Bio Inc  298380.KQ :
    * I-MAB AND ABL BIO ANNOUNCE LATEST UPDATES OF PD-L1 AND
4-1BB
BISPECIFIC ANTIBODY TJ-L14B/ABL503
    * I-MAB - PATENT RIGHTS SECURED FOR TJ-L14B/ABL503 IN
EURASIA
UNTIL 2039
    * I-MAB - AMONG 14 EFFICACY-EVALUABLE PATIENTS IN ONGOING
PHASE 1
STUDY, ONE ACHIEVED A COMPLETE RESPONSE
    * I-MAB -  AMONG 14 EFFICACY-EVALUABLE PATIENTS IN ONGOING
PHASE 1
STUDY, ONE HAD PARTIAL RESPONSE AND TWO UNCONFIRMED PARTIAL
RESPONSES
    * I-MAB - MAXIMUM TOLERATED DOSE NOT YET REACHED

Source text for Eikon:  ID:nPnbjClYTa 
Further company coverage:  298380.KQ 

 ((Reuters.Briefs@thomsonreuters.com))